Guzzardi Giuseppe, Fossaceca Rita, Moniaci Diego, Brustia Piero, Carriero Alessandro
Interventional Radiology 'Maggiore della Caritá' University Hospital, Novara, Italy.
Vascular. 2012 Apr;20(2):81-7. doi: 10.1258/vasc.2011.oa0312. Epub 2012 Apr 2.
The purpose of this study is to report our early experience with endovascular treatment of patients with symptomatic non-ruptured (sAAA) or ruptured (rAAA) abdominal aortic aneurysms. Between September 2005 and September 2008, all patients with a diagnosis of sAAA or rAAA were evaluated for endovascular suitability. We did not consider hemodynamic instability to be a contraindication for endovascular aneurysm repair (EVAR). Patients whose aneurysm anatomy was not suitable for EVAR received open repair (OR). A total of 46 patients with sAAA or rAAA underwent emergency EVAR: in particular, 18/46 patients were treated for sAAA and 28/46 for rAAA. Successful stent-graft deployment was achieved in 44 patients (96%); we had two open surgical conversions. The 30-day mortality rate was 19.5%. Nine patients died during the first 30 postoperative days: four patients died within 24 hours because of severe hypovolemic shock, two died of respiratory failure, one died as a result of bowel ischemia and two because of myocardial infarction after hospital discharge. Complete follow-up data were available for 35 patients (median 185 days; range 30-730 days). In conclusion, endovascular treatment is feasible and the early experience is promising. The capability of offering EVAR and OR for sAAA and rAAA according to our experience suggests that EVAR and OR should be regarded as complementary techniques to improve outcome of patients with acute AAA.
本研究的目的是报告我们对有症状的非破裂性(sAAA)或破裂性(rAAA)腹主动脉瘤患者进行血管内治疗的早期经验。在2005年9月至2008年9月期间,对所有诊断为sAAA或rAAA的患者进行了血管内治疗适用性评估。我们不认为血流动力学不稳定是血管内动脉瘤修复(EVAR)的禁忌证。动脉瘤解剖结构不适合EVAR的患者接受开放修复(OR)。共有46例sAAA或rAAA患者接受了急诊EVAR:具体而言,46例患者中有18例接受了sAAA治疗,28例接受了rAAA治疗。44例患者(96%)成功植入了支架移植物;我们有2例转为开放手术。30天死亡率为19.5%。9例患者在术后前30天内死亡:4例患者因严重低血容量性休克在24小时内死亡,2例死于呼吸衰竭,1例死于肠缺血,2例在出院后死于心肌梗死。35例患者有完整的随访数据(中位数185天;范围30 - 730天)。总之,血管内治疗是可行的,早期经验很有前景。根据我们的经验,能够为sAAA和rAAA提供EVAR和OR表明,EVAR和OR应被视为改善急性AAA患者预后的互补技术。